3 US Cannabis Giants Sued for Allegedly False Medical Claims

A sweeping federal class-action lawsuit was filed against Chicago-based cannabis giants Cresco Labs, Green Thumb Industries, and Verano Holdings, alleging they systematically deceived consumers with false medical claims while downplaying the health risks of their products.

"This lawsuit is part of a broader litigation campaign," Verano said in a statement, noting that similar claims have been rejected by courts. "Verano operates in compliance with applicable state laws and regulations, including the detailed product labeling, testing, and warning requirements dictated by each state."

The 317-page lawsuit, filed on behalf of 42 customers in a dozen states, seeks disgorgement of all profits, restitution for customers, and a prohibition on what it calls fraudulent medical claims. The suit alleges no personal injuries but claims customers overpaid based on misleading marketing, a tactic one study found on 67% of dispensary websites.

The litigation strikes at the heart of the cannabis industry's business model as it stands on the cusp of federal reform. With the Justice Department moving to reclassify marijuana to Schedule III—acknowledging medical use—this lawsuit challenges the very foundation of those medical claims and could create significant legal and financial headwinds for an industry still operating under federal illegality.

A Clash of Narratives

The lawsuit accuses the companies of working together through trade groups in a "conspiracy" to operate a fraudulent industry, promoting cannabis as a remedy for numerous ailments with insufficient scientific backing. It cites a 2025 Journal of the American Medical Association analysis of 124 studies that found "evidence is insufficient for the use of cannabis or cannabinoids for most medical indications." The American Psychiatric Association also stated there is "insufficient evidence" that cannabis is effective for any psychiatric disorder.

In its defense, Verano highlighted that both state medical programs and the federal government's recent rescheduling decision formally recognize the accepted medical use of cannabis. While evidence has shown cannabis to be effective for a narrow range of conditions like chemotherapy-induced nausea and certain types of epilepsy, the suit argues that widespread marketing claims go far beyond the science.

Federal Rescheduling Creates New Risks

The lawsuit comes at a pivotal moment. The federal government's move to reschedule marijuana from Schedule I to Schedule III acknowledges it has medical value, which would allow cannabis companies to take standard business tax deductions and open pathways for more research. However, this federal acceptance also brings greater scrutiny. If cannabis is a medicine, its claims could eventually be subject to the rigorous standards of the U.S. Food and Drug Administration (FDA).

This lawsuit represents a new legal battleground for the cannabis industry, shifting from state-level compliance to a direct challenge of the medical claims that underpin much of its market valuation. As the federal government moves toward rescheduling, the outcome of this case could influence how cannabis products are marketed, regulated, and valued for years to come, forcing companies to substantiate their health claims with rigorous scientific evidence or face significant financial penalties.

This article is for informational purposes only and does not constitute investment advice.